A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6μg and 160/18/9.6μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol - Rabe, KF; Martinez, FJ; Ferguson, GT; Wang, C; Singh, D; Wedzicha, JA; Trivedi, R; St, Rose E; Ballal, S; McLaren, J; Darken, P; Reisner, C; et al. (Respiratory Medicine, 2019)